FDA/DEA Letter Asks ADHD Drugmakers to Increase Production

The FDA and the Drug Enforcement Agency (DEA) have asked manufacturers to confirm they are working to increase production of their allotted quota of ADHD drugs to help resolve shortages.

In an Aug. 1 letter addressed to “Americans”, the FDA and DEA explained the steps they are taking to mitigate shortages of stimulant medications. “We are calling on key stakeholders, including manufacturers, distributors, pharmacies, and payors, to do all they can to ensure access for patients when a medication is appropriately prescribed,” the agencies wrote.

The letter explained that sales data submitted by manufacturers to the DEA showed that manufacturers only sold about 70 percent of their allotted quota for 2022, resulting in approximately one billion doses that they could have produced but did not make or ship. The trend is similar for 2023.

Read the FDA/DEA letter here.

To read the full story, click here to subscribe.

Related Topics